Calendario›ELOX›ELX-02

ELX-02

A Study of ELX-02 in Patients With Alport Syndrome

Ensayo de Eloxx Pharmaceuticals, Inc. en Alport Syndrome (del registro, en inglés).

Fase

Fase 2

Estado

Completado

Participantes

3

previstos

Centros

4

Fin del objetivo primario

sep 2023

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en nov 2022.

Qué mide

Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily (From the time of first dosing through the end of the follow-up period, a total of 5 months) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a Phase 2 open label pilot study to evaluate the safety and efficacy of subcutaneously administered ELX-02 in patients with X-linked or autosomal recessive Alport Syndrome with Col4A5 and Col4A3/4 nonsense mutation. In total, up to 8 participants, with a minimum of 3 adults, will be enrolled in the trial. The study will be comprised of the following periods for each participant: * a Screening period of up to 6 weeks (42 days) * a total Treatment Period of 8 weeks (60 days) * a safety/efficacy Follow-up Period of 12 weeks (90 days) after the last treatment The Treatment Period will be a treatment of ELX-02 0.75 mg/kg SC QD for 8 weeks.

Más ensayos de ELOX

Todos los de ELOX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05448755), actualizada en feb 2026.